羚锐品牌怎么样 申请店铺

我要投票 羚锐在中草药行业中的票数:462 更新时间:2025-07-25
羚锐是哪个国家的品牌?「羚锐」是 河南羚锐制药股份有限公司 旗下著名品牌。该品牌发源于河南,由创始人熊伟在1999-04-18期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力羚锐品牌出海!将品牌入驻外推网,定制羚锐品牌推广信息,可以显著提高羚锐产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

羚锐怎么样

河南羚锐制药股份有限公司始创于1992年6月,由河南省信阳羚羊山制药厂和香港锐星企业公司合资组建而成,2000年10月成功上市,成长为国内知名制药企业。目前,公司在北京、上海、武汉、郑州、信阳等地控股、参股十余家企业,拥有多个科研、生产基地,其中羚锐新县生态工业园为国内最大的橡胶膏剂药品生产基地,羚锐信阳科技园为国内先进的大型口服药生产基地,建立在北京的羚锐药物研究院和羚锐伟业科技有限公司为公司的科技研发基地。公司资产总额10亿元,年创利税逾亿元,已成为当地经济发展的支柱企业。

公司拥有橡胶膏剂、片剂、胶囊剂、颗粒剂、酊剂等十大剂型百余种产品,其中包括通络祛痛膏(骨质增生一贴灵)、培元通脑胶囊、丹鹿通督片、胃疼宁片、参芪降糖胶囊等独家拥有知识产权的产品及国家中药保护品种和国家医保药品。公司的所有产品剂型及其生产车间均通过国家GMP认证,质量标准实现了与国际接轨。

公司先后被评为“全国中药工业50强企业”、“全国中药系统先进集体”、“全国医药优秀企业”、“国家知识产权试点单位”,1999年和2005年先后两次被中央文明委表彰为“全国精神文明建设工作先进单位”,2001年被国家科技部认定为“国家火炬计划重点高新技术企业”,公司党委被中组部命名表彰为“全国先进基层党组织”;2002年“羚锐”商标被国家工商行政管理总局认定为“中国驰名商标”,成为国内橡胶膏剂药业中首件驰名商标。藉此,羚锐制药被业界誉为“中国橡胶膏剂药业第一品牌”。

浴火淬炼,十数年磨剑,羚锐始崛起,并稳健前进。

以“诚信立业,造福人类”为本,弘“团结、进取、创新、奉献”之志,坚持创新,实施人才兴企战略,以高新技术与传统药理、现代理念与先进文化完美融合,构筑企业平台,共享发展资源,我们将进一步提升核心竞争力,着力打造医药的优秀企业,成就百年基业。

Henan Lingrui Pharmaceutical Co., Ltd. was founded in June 1992 by Henan Xinyang lingyangshan pharmaceutical factory and Hong Kong Ruixing enterprise company. It was successfully listed in October 2000 and grew into a well-known pharmaceutical enterprise in China. At present, the company holds and shares more than ten enterprises in Beijing, Shanghai, Wuhan, Zhengzhou, Xinyang and other places, and has many scientific research and production bases. Among them, Lingrui new County Ecological Industrial Park is the largest rubber paste drug production base in China, Lingrui Xinyang science and technology park is the advanced large oral drug production base in China, and Lingrui Drug Research Institute and Lingrui Weiye science and technology established in Beijing Ltd. is the R & D base of the company. The company has a total assets of 1 billion yuan and an annual income tax of more than 100 million yuan, which has become a pillar enterprise of local economic development. The company has more than 100 kinds of products in ten dosage forms including rubber plaster, tablet, capsule, granule and tincture, including Tongluo Qutong plaster (hyperosteogeny Yitieling), Peiyuan Tongnao capsule, Danlu Tongdu tablet, Weitongning tablet, Shenqi Jiangtang Capsule and other products with exclusive intellectual property rights, national traditional Chinese medicine protection varieties and national medical insurance drugs. All the dosage forms and production workshops of the company have passed the national GMP certification, and the quality standards have been in line with the international standards. The company has been awarded as "top 50 enterprises of Chinese medicine industry", "advanced collective of Chinese medicine system", "excellent enterprise of Chinese medicine" and "pilot unit of national intellectual property". In 1999 and 2005, the company was awarded as "advanced unit of national spiritual civilization construction" by the central civilization Committee. In 2001, the company was recognized as "key high and new technology of national Torch Plan" by the Ministry of science and technology In 2002, "Lingrui" trademark was recognized as "China's well-known trademark" by the State Administration for Industry and commerce, and became the first well-known trademark in the domestic rubber paste pharmaceutical industry. Therefore, Lingrui pharmaceutical is known as "the first brand of Chinese rubber paste pharmaceutical industry". Bath fire quenching, more than ten years of sword sharpening, antelope sharp began to rise, and steady progress. Based on the principle of "building a business in good faith and benefiting mankind", we will carry out the strategy of "uniting, enterprising, innovating and dedicating", persist in innovation, carry out the strategy of developing an enterprise with talents, perfectly integrate high and new technology with traditional pharmacology, modern concept and advanced culture, build an enterprise platform and share development resources. We will further enhance our core competitiveness and strive to build an excellent enterprise in medicine, Achieve a century long foundation.

本文链接: https://brand.waitui.com/e8963bc9e.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

供需基本面有所改善,稀土价格持续上涨

上海钢联数据显示,7月24日国内氧化镨钕价格为52万元/吨,相较于年初已上涨30.5%。A股市场上,7月24日稀土、稀土永磁板块飘红,广晟有色、中科三环涨停,北方稀土盘中触及涨停。业内人士认为,当前稀土市场火热是供需和预期共振的结果。国内镨钕价格与美国国防部给美国稀土企业MP定的最低承诺价相比,尚有较大价差。另外,稀土供需层面的好转也为价格走强提供支撑。(上证报)

40分钟前

天风证券:八月的重点可能是“宽幅预喜行业”的非龙头个股

36氪获悉,据天风证券研报,7月中旬业绩预告披露,往往会提供一个业绩区间,宽幅区间的交易价值高于窄幅区间,存在“模糊溢价”。数据检验发现,7—8月的业绩窗口期,业绩预告上下限幅度更宽的板块超额更多;行业内个股看,宽幅预告的龙头的超额也更多。这个机制也一定程度解释了7—8月周期股有超额的日历效应。今年半年报来看,市场对于行业内的“宽幅预喜龙头”的超额定价可能已基本完成,但对“宽幅预喜行业”的超额定价还在路上。八月的重点可能是这类行业的非龙头个股,本质是扩散交易。

40分钟前

多只可转债将被赎回

7月24日泉峰转债迎来最后交易日。除泉峰转债外,精锻转债、恒辉转债、伟隆转债、北陆转债也将迎来最后交易日。业内人士认为,在新券供给未明显加快节奏情况下,下半年可转债市场规模或逐步缩减至6000亿元以下。展望后市,随着诸多利好释放,可转债市场有望在正股拉动以及增量资金入场下继续震荡走高。(中证网)

40分钟前

中信建投:重视商业航天投资机会

36氪获悉,中信建投研报称,我国低轨卫星互联网星座项目有望逐步向民营火箭开放,民营液体火箭将成为我国火箭发射资源的有力补充,并有望实现火箭发射成本的显著降低,加速我国卫星互联网建设,带动火箭、卫星产业链发展。民营火箭的技术及市场突破将显著带动产业链相关公司的发展,建议关注箭体结构件、液体火箭发动机结构件、传感器相关上市公司,同时还应重点关注火箭(特别是发动机)3D打印服务、3D打印设备相关上市公司。

40分钟前

全固态电池产业化进程提速

固态电池被视为全球动力电池下一代技术竞争的焦点。7月以来,多家企业披露了其在固态电池领域的最新进展,产业化进程明显提速。“从去年氧化物与硫化物的技术路线之争,到今年聚焦中试线建设进展,预计明年随着相关政策落地和产业规划相继实施,行业目光将转向谁能实现全固态电池装车应用。”有受访专家表示,固态电池商业化进程将不断加速。(中证网)

40分钟前

本页详细列出关于羚锐的品牌信息,含品牌所属公司介绍,羚锐所处行业的品牌地位及优势。
咨询